Literature DB >> 15655125

Parecoxib, valdecoxib, and cardiovascular risk.

Curt D Furberg, Bruce M Psaty, Garret A FitzGerald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15655125     DOI： 10.1161/01.CIR.0000155081.76164.17

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  16 in total

Review 1.  Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.

Authors:  Carlo Patrono
Journal:  Curr Cardiol Rep       Date:  2016-03       Impact factor: 2.931

2.  Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.

Authors:  Miao Wang; Alicia M Zukas; Yiqun Hui; Emanuela Ricciotti; Ellen Puré; Garret A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

Review 3.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Authors:  Tilo Grosser; Susanne Fries; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

Review 4.  Understanding the NSAID related risk of vascular events.

Authors:  Harald E Vonkeman; Jacobus R B J Brouwers; Mart A F J van de Laar
Journal:  BMJ       Date:  2006-04-15

Review 5.  An evidence-based update on nonsteroidal anti-inflammatory drugs.

Authors:  C K S Ong; P Lirk; C H Tan; R A Seymour
Journal:  Clin Med Res       Date:  2007-03

Review 6.  [Drugs for postoperative analgesia: routine and new aspects. Part 1: non-opioids].

Authors:  J Jage; R Laufenberg-Feldmann; F Heid
Journal:  Anaesthesist       Date:  2008-04       Impact factor: 1.041

Review 7.  Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Authors:  Ruth Savage
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 8.  NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.

Authors:  Jørgen Naesdal; Kurt Brown
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

9.  Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.

Authors:  Thomas J Montine; Joshua A Sonnen; Ginger Milne; Laura D Baker; John C S Breitner
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

10.  Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.

Authors:  Jonathan M Gitlin; Charles D Loftin
Journal:  Cardiovasc Res       Date:  2008-10-22       Impact factor: 10.787
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.